Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion

Rheumatology

Volumn 47, Issue 5, 2008, Pages 646-651

  Perricone, Roberto ^a   De Carolis, C ^b   Kroegler B ^a   Greco, E ^a   Giacomelli, R ^c   Cipriani, P ^c   Fontana, L ^a   Perricone, C ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b S Giacomo Hospital   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

APS; IVIg; Pregnancy; SLE

Indexed keywords

ACETYLSALICYLIC ACID; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LA ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPID ANTIBODY; PREDNISOLONE; RO ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADULT; APGAR SCORE; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; ITALY; OUTCOME ASSESSMENT; PERINATAL PERIOD; PREGNANCY; PREGNANCY OUTCOME; PRENATAL PERIOD; PRIORITY JOURNAL; PUERPERIUM; RATING SCALE; RECURRENT ABORTION; SPONTANEOUS ABORTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ABORTION, HABITUAL; ADULT; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTINUCLEAR; ASPIRIN; AUTOANTIBODIES; COMPLEMENT C3; COMPLEMENT C4; DNA; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREDNISOLONE; PREGNANCY; PREGNANCY OUTCOME;

EID: 42949130562     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken046     Document Type: Article

References (37)

1. Petri M. Systemic lupus erythematosus and pregnancy. Rheum Dis Clin North Am 1994;20:87-118.
2. Cervera R, Font J, Carmona F, Balasch J. Pregnancy outcome in systemic lupus erythematosus: Good news for the new millennium. Autoimmun Rev 2002;1:354-9.
3. Ioannou Y, Isenberg DA. Current concepts for the management of systemic lupus erythematosus in adults: A therapeutic challenge. Postgrad Med J 2002;78:599-606.
4. Mok CC, Wong RW. Pregnancy in systemic lupus erythematosus. Postgrad Med J 2001;77:157-65.
5. Tincani A, Rebaioli CB, Frassi M et al. Pregnancy Study Group of Italian Society of Rheumatology. Pregnancy and autoimmunity: Maternal treatment and maternal disease influence on pregnancy outcome. Autoimmun Rev 2005;4:423-8.
6. Gayed M, Gordon C. Pregnancy and rheumatic diseases. Rheumatology 2007; 46:1634-40.
7. Zandman-Goddard G, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol 2005;29:219-28.
8. Sherer Y, Shoenfeld Y. Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus. Autoimmun Rev 2006;5:153-5.
9. Shoenfeld Y, Katz U. IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity 2005;38:123-37.
10. Sony J. Intravenous immunoglobulin therapy for rheumatic diseases. Curr Opin Rheumatol 1994;6:305-10.
11. Triolo G, Ferrante A, Accardo-Palumbo A et al. IVIG in APS pregnancy. Lupus 2004;13:731-5.
12. Clark AL, Gall SA. Clinical uses of intravenous immunoglobulin in pregnancy. Am J Obstet Gynecol 1997;176:241-53.
13. De Carolis C, Greco E, Guarino MD et al. Anti-thyroid antibodies and antiphospholipid syndrome: Evidence of reduced fecundity and poor pregnancy outcome in recurrent spontaneous aborters. Am J Reprod Immunol 2004;52:263-6.
14. Levy Y, Sherer Y, Ahmed A et al. A study of 20 SLE patients with intravenous immunoglobulin, clinical and serologic response. Lupus 1999;8:705-12.
15. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 1999;42:1309-11.
16. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification: Criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
17. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
18. Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus a prospective cohort study. Arthritis Rheum 1991;34:937-44.
19. Ruiz-Irastorza G, Khamashta MA, Gordon C et al. Measuring systemic lupus erythematosus activity during pregnancy: Validation of the lupus activity index in pregnancy scale. Arthritis Rheum 2004;51:78-82.
20. Reber G, Tincani A, Sanmarco M, de Moerloose P, Boffa MC. Standardization group of the European Forum on Antiphospholipid Antibodies. Proposals for the measurement of anti-beta2-glycoprotein I antibodies. Standardization group of the European Forum on Antiphospholipid Antibodies. J Thromb Haemost 2004;2:1860-2.
21. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: An update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995;74:1185-90.
22. Agostoni A, Aygören-Pürsün E, Binkley KE et al. Hereditary and acPuired angioedema: Problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004;114 (3 Suppl):S51-131.
23. Meng C, Lockshin M. Pregnancy in lupus. Curr Opin Rheumatol 1999;11:348-51.
24. Pyne D, Ehrenstein M, Morris V. The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases. Rheumatology 2002;41:367-74.
25. Clark AL, Branch DW, Silver RM, Harris EN, Pierangeli S, Spinnato JA. Pregnancy complicated by the antiphospholipid syndrome: Outcomes with intravenous immunoglobulin therapy. Obstet Gynecol 1999;93:437-41.
26. Kessel A, Ammuri H, Peri R et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 2007;179:5571-5.
27. Perricone R, De Carolis C, Giacomelli R, Guarino MD, De Sanctis G, Fontana L. GM-CSF and pregnancy: Evidence of significantly reduced blood concentrations in unexplained recurrent abortion efficiently reverted by intravenous immunoglobulin treatment. Am J Reprod Immunol 2003;50:232-7.
28. Sultan Y, Kazatchine MD, Maisonneuve P, Nydegger UE. Antiidiotypic suppression of autoantibodies to Factor VIII (antihemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984;2:765-8.
29. Ruiz JE, Kwak JY, Baum L et al. Intravenous immunoglobulin inhibits natural killer cell activity in vivo in women with recurrent spontaneous abortion. Am J Reprod Immunol 1996;35:370-5.
30. De Placido G, Zullo F, Mollo A et al. Intravenous immunoglobulin (IVIg) in the prevention of implantation failures. Ann N Y Acad Sci 1994;734:232-4.
31. Perricone C, De Carolis C, Giacomelli R et al. High levels of NK cells in the peripheral blood of patients affected with antiphospholipid syndrome and recurrent spontaneous abortion: A potential new hypothesis. Rheumatology 2007;46:1574-8.
32. Perricone R, Di Muzio G, Perricone C et al. High levels of peripheral blood NK cells in women suffering from recurrent spontaneous abortion are reverted from high-dose intravenous immunoglobulins. Am J Reprod Immunol 2006;55:232-9.
33. Ruiz JE. Effect of intravenous immunoglobulin on natural killer cell activity in women with recurrent spontaneous abortion. Master Degree Thesis, Finch University of Health Science/The Chicago Medical School USA, 1995.
34. Dietrich G, Kaveri SV, Kazatchine MD. Modulation of autoimmunity by intravenous immunoglobulins through interaction with the function of the immune/idiotypic network. Clin Immunol 1992;62:S73-81.
35. Toubi E, Kessel A, Shoenfeld Y. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunol 2005;66:395-402.
36. Blank M, Anafi L, Zandman-Goddard G et al. The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): Trophoblast invasiveness and APS animal model. Int Immunol 2007;19:857-65.
37. Shoenfeld Y, Rauova L, Gilburd B et al. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol 2002;14:1303-11.